SEC Form 4 · accession 0001159036-26-000077
HALOZYME THERAPEUTICS, INC. · HALO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Mark Howard Snyder
Officer — SVP, CHIEF LEGAL OFFICER
Period of report
Jun 12, 2026
Accepted (ET)
Jun 15, 2026 · 4:09 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0001159036
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 12, 2026 | M | 5,034 | $0.00 | A | 52,644 | D | |
| Common StockF1 | Jun 12, 2026 | F | 2,715 | $69.50 | D | 49,929 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF2 | $0.00 | Jun 12, 2026 | M | 5,034 | D | — | — | Common Stock | 5,034 | 10,068 | D |
Explanation of responses
- F1The reported disposition of 2,715 shares represents the shares that were withheld by the issuer as payment for tax withholding obligations.
- F2This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the issuer.